Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study).
Hernández-Bernal F, Ricardo-Cobas MC, Martín-Bauta Y, Rodríguez-Martínez E, Urrutia-Pérez K, Urrutia-Pérez K, Quintana-Guerra J, Navarro-Rodríguez Z, Piñera-Martínez M, Rodríguez-Reinoso JL, Chávez-Chong CO, Baladrón-Castrillo I, Melo-Suárez G, Batista-Izquierdo A, Pupo-Micó A, Mora-Betancourt R, Bizet-Almeida J, Martínez-Rodríguez MC, Lobaina-Lambert L, Velázquez-Pérez VM, Soler-Díaz J, Laurencio-Vallina S, Meriño-Hechavarría T, Carmenaty-Campos N, Rodríguez-Montero E, Limonta-Fernández M, Alonso-Valdés M, Hernández-Rodríguez R, Pimentel-Vázquez E, Catasús-Álvarez KM, Cabrera-Núñez MV, Ayala-Ávila M, Muzio-González VL; ABDALA Research Group. Hernández-Bernal F, et al. Among authors: pinera martinez m. Lancet Reg Health Am. 2023 May 5;21:100497. doi: 10.1016/j.lana.2023.100497. eCollection 2023 May. Lancet Reg Health Am. 2023. PMID: 37192953 Free PMC article.
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).
Hernández-Bernal F, Ricardo-Cobas MC, Martín-Bauta Y, Navarro-Rodríguez Z, Piñera-Martínez M, Quintana-Guerra J, Urrutia-Pérez K, Urrutia-Pérez K, Chávez-Chong CO, Azor-Hernández JL, Rodríguez-Reinoso JL, Lobaina-Lambert L, Colina-Ávila E, Bizet-Almeida J, Rodríguez-Nuviola J, Del Valle-Piñera S, Ramírez-Domínguez M, Tablada-Ferreiro E, Alonso-Valdés M, Lemos-Pérez G, Guillén-Nieto GE, Palenzuela-Díaz A, Noa-Romero E, Limonta-Fernández M, Fernández-Ávila JM, Ali-Mros NA, Del Toro-Lahera L, Remedios-Reyes R, Ayala-Ávila M, Muzio-González VL. Hernández-Bernal F, et al. Among authors: pinera martinez m. EClinicalMedicine. 2022 Apr;46:101383. doi: 10.1016/j.eclinm.2022.101383. Epub 2022 Apr 9. EClinicalMedicine. 2022. PMID: 35434578 Free PMC article.
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1-2 Clinical Trial.
Lemos-Pérez G, Barrese-Pérez Y, Chacón-Quintero Y, Uranga-Piña R, Avila-Albuerne Y, Figueroa-García I, Calderín-Marín O, Gómez-Vázquez MM, Piñera-Martínez M, Chávez-Valdés S, Martínez-Rosales R, Ávila-Díaz L, Vázquez-Arteaga A, González-Formental H, Freyre-Corrales G, Coizeau-Rodríguez E, Limonta-Fernández M, Ayala-Avila M, Martínez-Díaz E, Pimentel-Vazquez E, Guillen G. Lemos-Pérez G, et al. Among authors: pinera martinez m. Vaccines (Basel). 2024 Sep 1;12(9):1001. doi: 10.3390/vaccines12091001. Vaccines (Basel). 2024. PMID: 39340031 Free PMC article.
[Reactive hepatitis caused by the hemorrhagic dengue virus].
del Valle Díaz S, Piñera Martínez M, Guasch Saent-Félix F. del Valle Díaz S, et al. Among authors: pinera martinez m. Rev Cubana Med Trop. 2001 Jan-Apr;53(1):28-31. Rev Cubana Med Trop. 2001. PMID: 11826534 Spanish.